Cargando…

Druggable Drivers of Lung Cancer

Detalles Bibliográficos
Autores principales:	Fawdar, Shameem, Edwards, Zoe C., Brognard, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2013
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824536/ https://www.ncbi.nlm.nih.gov/pubmed/23963079

Ejemplares similares

Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer
por: Seguin, Laetitia, et al.
Publicado: (2018)

Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer
por: Torres-Ayuso, Pedro, et al.
Publicado: (2022)

Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets
por: Torres-Ayuso, Pedro, et al.
Publicado: (2019)

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
por: Marusiak, Anna A., et al.
Publicado: (2014)

The PHLPP2 phosphatase is a druggable driver of prostate cancer progression
por: Nowak, Dawid G., et al.
Publicado: (2019)

Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets
por: Chen, Ying, et al.
Publicado: (2014)

New Therapeutic Opportunities for the Treatment of Squamous Cell Carcinomas: A Focus on Novel Driver Kinases
por: Bensen, Ryan, et al.
Publicado: (2021)

Correction: Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets
Publicado: (2014)

Druggable Targets of Squamous Cell Lung Cancer
por: Kim, Cheol Hyeon
Publicado: (2013)

The novel driver gene ASAP2 is a potential druggable target in pancreatic cancer
por: Fujii, Atsushi, et al.
Publicado: (2021)

The Tumor Microenvironment: A Druggable Target for Metastatic Disease?
por: EBioMedicine
Publicado: (2018)

FAP: Not Just a Biomarker but Druggable Target in Liver Fibrosis
por: Kim, Jieun, et al.
Publicado: (2023)

Anti-Neurodegenerating Activity: Structure–Activity Relationship Analysis of Flavonoids
por: Preet, Gagan, et al.
Publicado: (2023)

VAV2: a novel prognostic marker and a druggable target for adrenocortical carcinoma
por: Ruggiero, Carmen, et al.
Publicado: (2017)

Esophageal Adenocarcinomas: A Need for Speed Driven by Immune Pathways That Have Druggable Targets
por: Souza, Rhonda F.
Publicado: (2018)

Druggable driver gene alterations in redefined large cell carcinoma in Chinese patients: an observational study
por: Yang, Jinhua, et al.
Publicado: (2020)

Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas
por: van de Geer, Wesley S, et al.
Publicado: (2021)

The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer
por: Cerrato, Aniello, et al.
Publicado: (2018)

Druggable genetic targets in endometrial cancer
por: Lehrer, Steven, et al.
Publicado: (2022)

Targeted Therapies and Druggable Genetic Anomalies in Acute Myeloid Leukemia: From Diagnostic Tools to Therapeutic Interventions
por: Lanza, Francesco, et al.
Publicado: (2021)

Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer
por: Christopoulos, Petros
Publicado: (2023)

KRAS: Druggable at Last
por: Herzberg, Benjamin O, et al.
Publicado: (2023)

The Druggable Pocketome of Corynebacterium diphtheriae: A New Approach for in silico Putative Druggable Targets
por: Hassan, Syed S., et al.
Publicado: (2018)

Beyond finding druggable targets and tumor mutational burden: to measure heterogeneity by ctDNA
por: Liu, Zhichao, et al.
Publicado: (2020)

DGIdb - Mining the druggable genome
por: Griffith, Malachi, et al.
Publicado: (2013)

Dissecting phenotypic responses of the druggable targetome in cancers
por: Jeong, Euna, et al.
Publicado: (2019)

Cysteine metabolic circuitries: druggable targets in cancer
por: Bonifácio, Vasco D. B., et al.
Publicado: (2020)

KRAS mutation: from undruggable to druggable in cancer
por: Huang, Lamei, et al.
Publicado: (2021)

Systematic illumination of druggable genes in cancer genomes
por: Jiang, Junjie, et al.
Publicado: (2022)

Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer
por: Fois, Sara S., et al.
Publicado: (2021)

Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards
por: Danesi, R., et al.
Publicado: (2021)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions
por: Li, Binghao, et al.
Publicado: (2021)

Drivers of Esophageal Adenocarcinoma and Opportunities for Cancer Interception
por: Garman, Katherine S.
Publicado: (2021)

KRAS: A Druggable Target in Colon Cancer Patients
por: Negri, Francesca, et al.
Publicado: (2022)

Optimal Therapy for Advanced Non-Small Cell Lung Cancer Without Driver Alterations
por: Pacheco, Jose, et al.
Publicado: (2021)

Reading Cancer: Chromatin Readers as Druggable Targets for Cancer Treatment
por: Mio, Catia, et al.
Publicado: (2019)

An integrated structural proteomics approach along the druggable genome of Corynebacterium pseudotuberculosis species for putative druggable targets
por: Radusky, Leandro G, et al.
Publicado: (2015)

Orange is the new black: Kinases are the new master regulators of tumor suppression
por: An, Elvira, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ibl57qmfhvnure8t90ocinpp9v